MA49141A - Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau - Google Patents

Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau

Info

Publication number
MA49141A
MA49141A MA049141A MA49141A MA49141A MA 49141 A MA49141 A MA 49141A MA 049141 A MA049141 A MA 049141A MA 49141 A MA49141 A MA 49141A MA 49141 A MA49141 A MA 49141A
Authority
MA
Morocco
Prior art keywords
pyrrolopyridine
treatment
skin conditions
aniline compounds
aniline
Prior art date
Application number
MA049141A
Other languages
English (en)
Inventor
Matthew Duncton
John Kincaid
Original Assignee
Nflection Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nflection Therapeutics Inc filed Critical Nflection Therapeutics Inc
Publication of MA49141A publication Critical patent/MA49141A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA049141A 2017-05-19 2018-05-18 Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau MA49141A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762508997P 2017-05-19 2017-05-19
US201862663202P 2018-04-26 2018-04-26

Publications (1)

Publication Number Publication Date
MA49141A true MA49141A (fr) 2020-03-25

Family

ID=62620966

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049141A MA49141A (fr) 2017-05-19 2018-05-18 Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau

Country Status (16)

Country Link
US (4) US11161845B2 (fr)
EP (1) EP3624796B1 (fr)
JP (1) JP7212956B2 (fr)
KR (1) KR102642411B1 (fr)
CN (1) CN111065393B (fr)
AU (1) AU2018270295B2 (fr)
CA (1) CA3063536A1 (fr)
DK (1) DK3624796T3 (fr)
ES (1) ES3030506T3 (fr)
FI (1) FI3624796T3 (fr)
IL (1) IL270752B (fr)
MA (1) MA49141A (fr)
MX (2) MX389965B (fr)
PL (1) PL3624796T3 (fr)
PT (1) PT3624796T (fr)
WO (1) WO2018213810A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3063535A1 (fr) 2017-05-19 2018-11-22 Nflection Therapeutics, Inc. Composes heteroaromatiques-aniline fusionnes pour le traitement de troubles dermiques
MA49141A (fr) * 2017-05-19 2020-03-25 Nflection Therapeutics Inc Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau
MA55141A (fr) 2018-11-20 2021-09-29 Nflection Therapeutics Inc Composés cyanoaryl-aniline pour le traitement d'affections de la peau
JP7546297B2 (ja) 2018-11-20 2024-09-06 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのチエニル－アニリン化合物
CA3120351A1 (fr) * 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Composes aryl-aniline et heteroaryl-aniline pour le traitement de cancers de la peau
US12378240B2 (en) 2018-11-20 2025-08-05 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
EP4233834A3 (fr) * 2018-11-20 2023-10-25 NFlection Therapeutics, Inc. Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance
IL301496A (en) * 2020-09-24 2023-05-01 Nflection Therapeutics Inc Treatment of cognitive dysfunction with pyrrolopyridine-aniline compounds
EP4281055A4 (fr) * 2021-01-21 2025-06-18 NFlection Therapeutics, Inc. Formes cristallines d'un composé de pyrrolopyridine-aniline
JP2024503893A (ja) * 2021-01-21 2024-01-29 エヌフレクション セラピューティクス インコーポレイテッド ピロロピリジン－アニリン化合物を調製するための方法
WO2023096935A1 (fr) * 2021-11-23 2023-06-01 Nflection Therapeutics, Inc. Formulations de composés de pyrrolopyridine-aniline
IL312977A (en) 2021-11-23 2024-07-01 Nflection Therapeutics Inc Formulations of pyrrolopyridine-aniline compounds
JP2025508195A (ja) * 2022-03-17 2025-03-21 スプリングワークス、セラピューティクス、インコーポレイテッド 小児患者における神経線維腫症１型（ｎｆ１）に関連する叢状神経線維腫（ｐｎ）のミルダメチニブによる治療

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
WO1997001331A2 (fr) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Production de preparations a liberation prolongee
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (fr) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Formulation a liberation-retard
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
ZA9711385B (en) 1996-12-20 1999-06-18 Takeda Chemical Industries Ltd Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7674907B2 (en) 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use
MX2007009335A (es) 2005-02-02 2007-12-07 Nexgenix Pharmaceuticals L L C Tratamiento local de neurofibromas.
DK2395004T3 (en) * 2005-06-22 2016-03-21 Plexxikon Inc Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors
GB0601962D0 (en) * 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
GB0616214D0 (en) 2006-08-15 2006-09-27 Ucb Sa Therapeutic Agents
WO2008024725A1 (fr) 2006-08-21 2008-02-28 Genentech, Inc. Composés aza-benzofuranyle et leurs procédés d'utilisation
EP2069359B1 (fr) 2006-08-21 2014-11-12 Genentech, Inc. Composés aza-benzothiophényle et leurs procédés d'utilisation
EP2113500A1 (fr) 2006-10-31 2009-11-04 Takeda Pharmaceutical Company Limited Inhibitêur du kinàse MAPK/ERK
CA2672327A1 (fr) * 2006-11-30 2008-06-05 Genentech, Inc. Composes azaindolyliques et procedes d'utilisation de ceux-ci
WO2008148034A1 (fr) 2007-05-25 2008-12-04 Takeda Pharmaceutical Company Limited Inhibiteurs de mapk/erk kinase
ES2387707T3 (es) 2007-12-21 2012-09-28 Genentech, Inc. Azaindolizinas y procedimientos de uso
EP2240494B1 (fr) 2008-01-21 2016-03-30 UCB Biopharma SPRL Dérivés de thiénopyridine utilisés comme inhibiteurs de mek
GB0801081D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
GB0801080D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
US8450344B2 (en) * 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US9422262B2 (en) 2010-09-24 2016-08-23 The Broad Institute, Inc. Compounds and methods for treating diseases mediated by protease activated receptors
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
WO2014179785A1 (fr) 2013-05-03 2014-11-06 Inscent, Inc. Répulsifs améliorés contre les abeilles domestiques et leurs utilisations
CN105384754B (zh) 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
MA49141A (fr) * 2017-05-19 2020-03-25 Nflection Therapeutics Inc Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau

Also Published As

Publication number Publication date
EP3624796B1 (fr) 2025-03-19
CN111065393B (zh) 2023-08-18
WO2018213810A1 (fr) 2018-11-22
MX2019013561A (es) 2022-02-09
EP3624796A1 (fr) 2020-03-25
IL270752B (en) 2022-06-01
AU2018270295A1 (en) 2019-12-05
US20250388580A1 (en) 2025-12-25
MX2022001697A (es) 2022-04-07
DK3624796T3 (da) 2025-06-02
US20200165243A1 (en) 2020-05-28
JP2020520995A (ja) 2020-07-16
MX389965B (es) 2025-03-20
ES3030506T3 (en) 2025-06-30
US20250034137A1 (en) 2025-01-30
PL3624796T3 (pl) 2025-06-30
US12428418B2 (en) 2025-09-30
US12065439B2 (en) 2024-08-20
PT3624796T (pt) 2025-06-02
CA3063536A1 (fr) 2018-11-22
FI3624796T3 (fi) 2025-06-11
US20220033399A1 (en) 2022-02-03
US11161845B2 (en) 2021-11-02
CN111065393A (zh) 2020-04-24
KR20200013239A (ko) 2020-02-06
AU2018270295B2 (en) 2022-03-03
JP7212956B2 (ja) 2023-01-26
KR102642411B1 (ko) 2024-02-28
IL270752A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
IL271046A (en) Compounds for treating huntington's disease
EP3911313A4 (fr) Composés thiényl-aniline destinés au traitement d'affections de la peau
MA52575A (fr) Pansement pour le traitement de la peau endommagée
EP3448389A4 (fr) Composés de quinazoline et d'indole destinés au traitement de troubles médicaux
EP2812004A4 (fr) Composés destinés au traitement de l'amyotrophie spinale
EP3704108A4 (fr) Composés et compositions pour le traitement de troubles hématologiques
EP3784260A4 (fr) Compositions pour le traitement d'affections cutanées
IL286340A (en) Topical formulations for treatment of peripheral neuropathies
PL3405215T3 (pl) Sposoby leczenia choroby danona i innych zaburzeń autofagii
MA46524A (fr) Composés de biphényl-sulfonamide destinés au traitement de néphropathies
EP3883553A4 (fr) Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau
EP3790563A4 (fr) Compositions permettant le traitement d'affections cutanées
EP4045036C0 (fr) Amides hétéroaryle-biphényle pour le traitement de maladies associées à pd-l1
EP3664812A4 (fr) Compositions topiques pour la peau destinées au traitement de l'érythème ou de l'inflammation cutanée
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
HUE071155T2 (hu) Biszkolin-tetratiomolibdát Wilson-kór kezelésére
MA55144A (fr) Composés naphthyridinone-aniline destinés au traitement d'affections de la peau
EP3672587A4 (fr) Compositions pharmaceutiques destinées au traitement d'affections ophtalmiques
EP3773632A4 (fr) Méthodes de traitement de glioblastomes exprimant l'egfrviii
LT3463351T (lt) Parkinsono ligos gydymas
EP3538219A4 (fr) Compositions topiques destinées au traitement de l'acné
EP3883552A4 (fr) Composés cyanoaryl-aniline pour le traitement d'affections de la peau
IL270900A (en) Treatment of cutaneous disorders
EP3593803A4 (fr) Composés destinés au traitement de maladies causées par l'accumulation d'oxalate
MA51738A (fr) Composés pour le traitement de la douleur